Akebia Therapeutics (AKBA) Stock Price, News & Analysis

Company Overview

Akebia Therapeutics, Inc. is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for patients with kidney disease. Founded in 2007 and headquartered in Cambridge, Massachusetts, Akebia’s mission is to improve the lives of patients suffering from renal disorders, particularly chronic kidney disease (CKD). The company leverages its expertise in hypoxia‐inducible factor (HIF) biology to create novel treatments aimed at addressing anemia associated with CKD and other serious conditions.

The company’s leading product candidate, vadadustat, is an oral HIF prolyl‐hydroxylase inhibitor designed to treat anemia in both non‐dialysis and dialysis‐dependent CKD patients. Vadadustat seeks to offer an alternative to injectable erythropoiesis‐stimulating agents by promoting endogenous erythropoietin production and improving iron mobilization. In addition to vadadustat, Akebia maintains a pipeline of early‐stage programs targeting other indications where HIF modulation may provide therapeutic benefit.

Akebia operates globally through strategic partnerships and collaborations. In 2014, the company entered into a licensing and collaboration agreement with Otsuka Pharmaceutical Co., Ltd., which granted rights to develop and commercialize vadadustat in key markets including the United States, Europe, Japan, China and other territories. This alliance has enabled Akebia to combine its scientific capabilities with Otsuka’s regulatory and commercial infrastructure, accelerating the advancement of vadadustat through pivotal clinical trials and regulatory review processes across multiple regions.

Leadership at Akebia comprises seasoned executives and scientists with extensive experience in drug development and commercialization. The company’s management team is led by a Board of Directors with backgrounds in biotechnology, nephrology and pharmaceutical operations. Since its inception, Akebia has built a strong governance framework and has been guided by a commitment to scientific rigor, patient‐centricity and long‐term value creation in the renal care community.

Key Stats

• Today's Range: $3.56 to $3.63
• 50-Day Range: $2.32 to $3.97
• 52-Week Range: $0.92 to $4.08
• Volume: 1.57 million shs
• Average Volume: 3.16 million shs
• Market Capitalization: $946.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.75
• Consensus Rating: Buy

Akebia Therapeutics Stock Analysis - MarketRank™

Akebia Therapeutics scored higher than 85% of companies evaluated by MarketBeat, and ranked 148th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Akebia Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Akebia Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Akebia Therapeutics are expected to grow in the coming year, from ($0.30) to ($0.14) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Akebia Therapeutics is -17.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Akebia Therapeutics is -17.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.26% of the float of Akebia Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Akebia Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Akebia Therapeutics has recently decreased by 7.73%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Akebia Therapeutics does not currently pay a dividend.

Dividend Growth

Akebia Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.0 / 5
• Environmental Score: -1.35

Percentage of Shares Shorted

7.26% of the float of Akebia Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Akebia Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Akebia Therapeutics has recently decreased by 7.73%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.63

News Sentiment

Akebia Therapeutics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Akebia Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 11 people have searched for AKBA on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Akebia Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Akebia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $258,841.00 in company stock.

Percentage Held by Insiders

Only 3.00% of the stock of Akebia Therapeutics is held by insiders.

Percentage Held by Institutions

Only 33.92% of the stock of Akebia Therapeutics is held by institutions.

AKBA Stock Analysis - Frequently Asked Questions

How have AKBA shares performed this year?

Akebia Therapeutics' stock was trading at $1.90 at the beginning of 2025. Since then, AKBA stock has increased by 89.7% and is now trading at $3.6050.

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics, Inc. (NASDAQ:AKBA) posted its quarterly earnings results on Thursday, May, 8th. The biopharmaceutical company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.06. The biopharmaceutical company had revenue of $57.34 million for the quarter, compared to the consensus estimate of $44.88 million.
Read the conference call transcript.

How do I buy shares of Akebia Therapeutics?

Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Akebia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Akebia Therapeutics investors own include Novavax (NVAX), NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC) and Exxon Mobil (XOM).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/06/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AKBA
• CIK: 1517022
• Web: www.akebia.com
• Phone: (617) 871-2098
• Fax: 617-871-2099
• Employees: 430
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.75
• High Stock Price Target: $8.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: +87.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$69.41 million
• Net Margins: -24.51%
• Pretax Margin: -24.51%
• Return on Equity: N/A
• Return on Assets: -18.92%

Debt

• Debt-to-Equity Ratio: 1.89
• Current Ratio: 2.23
• Quick Ratio: 2.02

Sales & Book Value

• Annual Sales: $184.91 million
• Price / Sales: 5.12
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.23) per share
• Price / Book: -15.67

Miscellaneous

• Outstanding Shares: 262,636,000
• Free Float: 254,757,000
• Market Cap: $946.80 million
• Optionable: Optionable
• Beta: 0.88